CN109069491A - 毒蕈碱型乙酰胆碱受体m1的正向别构调节剂 - Google Patents

毒蕈碱型乙酰胆碱受体m1的正向别构调节剂 Download PDF

Info

Publication number
CN109069491A
CN109069491A CN201780023438.3A CN201780023438A CN109069491A CN 109069491 A CN109069491 A CN 109069491A CN 201780023438 A CN201780023438 A CN 201780023438A CN 109069491 A CN109069491 A CN 109069491A
Authority
CN
China
Prior art keywords
methyl
pyridine
thieno
carboxamide
ylphenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201780023438.3A
Other languages
English (en)
Chinese (zh)
Inventor
C.W.林兹利
P.J.康恩
D.W.恩格斯
K.A.博林杰
J.L.恩格斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vanderbilt University
Original Assignee
Vanderbilt University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vanderbilt University filed Critical Vanderbilt University
Publication of CN109069491A publication Critical patent/CN109069491A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Anesthesiology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Psychology (AREA)
  • Immunology (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CN201780023438.3A 2016-02-16 2017-02-16 毒蕈碱型乙酰胆碱受体m1的正向别构调节剂 Pending CN109069491A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662296012P 2016-02-16 2016-02-16
US62/296012 2016-02-16
US201662402438P 2016-09-30 2016-09-30
US62/402438 2016-09-30
PCT/US2017/018140 WO2017143041A1 (en) 2016-02-16 2017-02-16 Positive allosteric modulators of the muscarinic acetylcholine receptor m1

Publications (1)

Publication Number Publication Date
CN109069491A true CN109069491A (zh) 2018-12-21

Family

ID=59626207

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780023438.3A Pending CN109069491A (zh) 2016-02-16 2017-02-16 毒蕈碱型乙酰胆碱受体m1的正向别构调节剂

Country Status (15)

Country Link
US (1) US11111251B2 (https=)
EP (1) EP3416639B1 (https=)
JP (1) JP2019504901A (https=)
KR (1) KR20180110132A (https=)
CN (1) CN109069491A (https=)
AU (1) AU2017221404A1 (https=)
BR (1) BR112018016689A2 (https=)
CA (1) CA3014791A1 (https=)
CL (1) CL2018002335A1 (https=)
EA (1) EA201891854A1 (https=)
IL (1) IL261058A (https=)
MA (1) MA44253A (https=)
MX (1) MX385975B (https=)
PH (1) PH12018501731A1 (https=)
WO (1) WO2017143041A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109952302A (zh) * 2016-09-02 2019-06-28 苏文生命科学有限公司 毒蕈碱m1受体正向别构调节剂

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA035599B1 (ru) * 2017-04-13 2020-07-14 Сувен Лайф Сайенсиз Лимитед Позитивные аллостерические модуляторы мускариновых m1-рецепторов
WO2018235838A1 (ja) 2017-06-20 2018-12-27 武田薬品工業株式会社 複素環化合物
CA3068209A1 (en) * 2017-06-20 2018-12-27 Takeda Pharmaceutical Company Limited Heterocyclic compound
US12600726B2 (en) 2017-07-12 2026-04-14 Vanderbilt University Antagonists of the muscarinic acetylcholine receptor M4
IL310346A (en) 2017-10-20 2024-03-01 Univ Vanderbilt Muscarinic acetylcholine M4 receptor antagonists
MA50464A (fr) * 2017-10-27 2021-06-02 Suven Life Sciences Ltd Amides polycycliques utilisés en tant que modulateurs allostériques positifs du récepteur muscarinique m1
AU2018360581A1 (en) 2017-10-31 2020-06-11 Vanderbilt University Antagonists of the muscarinic acetylcholine receptor M4
CN111788182B (zh) 2018-02-02 2023-09-26 范德堡大学 毒蕈碱性乙酰胆碱受体m4的拮抗剂
US11851406B2 (en) * 2018-06-13 2023-12-26 Vanderbilt University Positive allosteric modulators of the muscarinic acetylcholine receptor M1
EP3858823A4 (en) 2018-09-28 2022-07-06 Takeda Pharmaceutical Company Limited Condensed-cyclic compound
EP3858828A4 (en) 2018-09-28 2022-07-06 Takeda Pharmaceutical Company Limited HETEROCYCLIC COMPOUND
WO2020086864A1 (en) 2018-10-24 2020-04-30 Vanderbilt University Positive allosteric modulators of the muscarinic acetylcholine receptor m1
EP3643711A1 (en) * 2018-10-24 2020-04-29 Bayer Animal Health GmbH New anthelmintic compounds
AU2020358000A1 (en) * 2019-10-04 2022-04-07 Vanderbilt University Antagonists of the muscarinic acetylcholine receptor M4

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140200222A1 (en) * 2011-05-17 2014-07-17 Scott D. Kuduk N-linked quinolineamide m1 receptor positive allosteric modulators

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4608079A (en) 1983-08-02 1986-08-26 American Cyanamid Company Imidazolidinones, and imidazolidinethiones, process and intermediates for the preparation thereof, and use of said compounds as herbicidal agents
DE4129603A1 (de) * 1991-09-06 1993-03-11 Thomae Gmbh Dr K Kondensierte 5-gliedrige heterocyclen, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
JP2002539130A (ja) 1999-03-09 2002-11-19 ファルマシア・アンド・アップジョン・カンパニー 抗ウイルス剤としての４−オキソ−４，７−ジヒドロ−チエノ［２，３−ｂ］ピリジン−５−カルボキサミド
CN1249051C (zh) 2000-04-28 2006-04-05 阿卡蒂亚药品公司 毒蕈碱性激动剂
HUP0402289A2 (hu) * 2001-10-02 2005-02-28 Pharmacia & Upjohn Company Gyógyhatású azabiciklusos csoporttal helyettesített kondenzált heteroaril-származékok, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
US9199939B2 (en) * 2009-12-17 2015-12-01 Merck Sharp & Dohme Corp. Quinoline amide M1 receptor positive allosteric modulators
WO2011159554A1 (en) 2010-06-15 2011-12-22 Merck Sharp & Dohme Corp. Tetrahydroquinoline amide m1 receptor positive allosteric modulators
WO2015027204A1 (en) 2013-08-23 2015-02-26 Vanderbilt University Substituted thieno[2,3-b]pyridine-2-carboxamide analogs as positive allosteric modulators of the muscarinic acetylcholine receptor m4
TW201512197A (zh) 2013-08-30 2015-04-01 Hoffmann La Roche 吡咯并吡啶或吡唑并吡啶衍生物
GB201317363D0 (en) * 2013-10-01 2013-11-13 Eisai Ltd Novel compounds
CA2930961A1 (en) 2014-01-22 2015-07-30 F. Hoffmann-La Roche Ag Fluoro-naphthyl derivatives
WO2015190564A1 (ja) * 2014-06-13 2015-12-17 武田薬品工業株式会社 含窒素複素環化合物
WO2016009297A1 (en) * 2014-07-18 2016-01-21 Pfizer Inc. Pyridine derivatives as muscarinic m1 receptor positive allosteric modulators
WO2016029454A1 (en) 2014-08-29 2016-03-03 Merck Sharp & Dohme Corp. TETRAHYDRONAPHTHYRIDINE DERIVATIVES AS mGluR2-NEGATIVE ALLOSTERIC MODULATORS, COMPOSITIONS, AND THEIR USE
MX389592B (es) 2016-09-02 2025-03-20 Suven Life Sciences Ltd Moduladores alostericos positivos del receptor m1 muscarinico

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140200222A1 (en) * 2011-05-17 2014-07-17 Scott D. Kuduk N-linked quinolineamide m1 receptor positive allosteric modulators

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109952302A (zh) * 2016-09-02 2019-06-28 苏文生命科学有限公司 毒蕈碱m1受体正向别构调节剂

Also Published As

Publication number Publication date
WO2017143041A1 (en) 2017-08-24
EP3416639B1 (en) 2022-06-08
MX2018009952A (es) 2018-11-29
EP3416639A4 (en) 2019-07-03
KR20180110132A (ko) 2018-10-08
IL261058A (en) 2018-10-31
US20210230180A1 (en) 2021-07-29
MA44253A (fr) 2018-12-26
US11111251B2 (en) 2021-09-07
MX385975B (es) 2025-03-18
EP3416639A1 (en) 2018-12-26
JP2019504901A (ja) 2019-02-21
PH12018501731A1 (en) 2019-06-17
AU2017221404A1 (en) 2018-08-23
CL2018002335A1 (es) 2019-02-01
EA201891854A1 (ru) 2019-01-31
CA3014791A1 (en) 2017-08-24
BR112018016689A2 (pt) 2019-02-12

Similar Documents

Publication Publication Date Title
CN109069491A (zh) 毒蕈碱型乙酰胆碱受体m1的正向别构调节剂
US12577234B2 (en) Antagonists of the muscarinic acetylcholine receptor M4
CN109310668A (zh) 毒蕈碱型乙酰胆碱受体m4的正向别构调节剂
EP3651762B1 (en) Antagonists of the muscarinic acetylcholine receptor m4
CN109890388B (zh) 毒蕈碱型乙酰胆碱受体m4的正向别构调节剂
CN112601749A (zh) 用于治疗认知损害的苯并二氮杂环庚三烯衍生物，组合物和方法
JP7099725B2 (ja) ムスカリン性アセチルコリンレセプターｍ４のポジティブアロステリック調節因子
CN111788182A (zh) 毒蕈碱性乙酰胆碱受体m4的拮抗剂
CN109863139A (zh) 毒蕈碱型乙酰胆碱受体m4的正向别构调节剂
TWI358298B (en) Substituted 4-alkyl- and 4-alkanoyl-piperidine der
US20190330226A1 (en) Positive allosteric modulators of the muscarinic acetylcholine receptor m1
US20240182445A1 (en) Modulators of trek (twik related k+ channels) channel function
JP2021505581A (ja) ムスカリン性アセチルコリンレセプターｍ４のポジティブアロステリック調節因子
US20240190824A1 (en) Inhibitors of trek (twik related k+ channels) channel function
CN109071457A (zh) 吲哚胺2,3-双加氧酶的抑制剂
HK40049071A (en) Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20181221